ChartMill assigns a Buy % Consensus number of 46% to GRTX. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-08-29 | Citigroup | Maintains | Neutral -> Neutral |
| 2023-08-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-08-10 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-07-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-22 | HC Wainwright & Co. | Maintains | Buy |
| 2023-02-21 | Piper Sandler | Initiate | Overweight |
| 2023-02-16 | B of A Securities | Upgrade | Underperform -> Buy |
| 2023-02-16 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-05-27 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2021-12-20 | Citigroup | Maintains | Buy |
| 2021-12-15 | BTIG | Upgrade | Neutral -> Buy |
| 2021-12-15 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2021-10-20 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-10-19 | BTIG | Downgrade | Buy -> Neutral |
7 analysts have analysed GRTX and the average price target is 0.38 USD. This implies a price increase of 163.79% is expected in the next year compared to the current price of 0.145.
The consensus rating for GALERA THERAPEUTICS INC (GRTX) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering GALERA THERAPEUTICS INC (GRTX) is 7.